325 related articles for article (PubMed ID: 16859791)
21. A computational model of Parkinsonian handwriting that highlights the role of the indirect pathway in the basal ganglia.
Gangadhar G; Joseph D; Srinivasan AV; Subramanian D; Shivakeshavan RG; Shobana N; Chakravarthy VS
Hum Mov Sci; 2009 Oct; 28(5):602-18. PubMed ID: 19720411
[TBL] [Abstract][Full Text] [Related]
22. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
Müller T; Benz S; Börnke C; Przuntek H
Acta Neurol Scand; 2004 May; 109(5):348-54. PubMed ID: 15080862
[TBL] [Abstract][Full Text] [Related]
23. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
Tomer R; Aharon-Peretz J; Tsitrinbaum Z
Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
[TBL] [Abstract][Full Text] [Related]
24. Perturbation of a prehension movement in Parkinson's disease.
Scarpa M; Castiello U
Mov Disord; 1994 Jul; 9(4):415-25. PubMed ID: 7969208
[TBL] [Abstract][Full Text] [Related]
25. Word processing in Parkinson's disease is impaired for action verbs but not for concrete nouns.
Boulenger V; Mechtouff L; Thobois S; Broussolle E; Jeannerod M; Nazir TA
Neuropsychologia; 2008 Jan; 46(2):743-56. PubMed ID: 18037143
[TBL] [Abstract][Full Text] [Related]
26. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
[TBL] [Abstract][Full Text] [Related]
27. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
28. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
29. Beating a dead horse: dopamine and Parkinson disease.
Ahlskog JE
Neurology; 2007 Oct; 69(17):1701-11. PubMed ID: 17954785
[TBL] [Abstract][Full Text] [Related]
30. Voluntary, spontaneous, and reflex blinking in Parkinson's disease.
Agostino R; Bologna M; Dinapoli L; Gregori B; Fabbrini G; Accornero N; Berardelli A
Mov Disord; 2008 Apr; 23(5):669-75. PubMed ID: 18175339
[TBL] [Abstract][Full Text] [Related]
31. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements.
Mallol R; Barrós-Loscertales A; López M; Belloch V; Parcet MA; Avila C
Brain Res; 2007 May; 1147():265-71. PubMed ID: 17368575
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of handwriting of patients with Huntington's disease.
Phillips JG; Bradshaw JL; Chiu E; Bradshaw JA
Mov Disord; 1994 Sep; 9(5):521-30. PubMed ID: 7990847
[TBL] [Abstract][Full Text] [Related]
33. Death in the substantia nigra: a motor tragedy.
Esposito E; Di Matteo V; Di Giovanni G
Expert Rev Neurother; 2007 Jun; 7(6):677-97. PubMed ID: 17563251
[TBL] [Abstract][Full Text] [Related]
34. Effect of medication in Parkinson's disease: a wavelet analysis of EMG signals.
Strambi SK; Rossi B; De Michele G; Sello S
Med Eng Phys; 2004 May; 26(4):279-90. PubMed ID: 15121053
[TBL] [Abstract][Full Text] [Related]
35. Saccadometry: a novel clinical tool for quantification of the motor effects of subthalamic nucleus stimulation in Parkinson's disease.
Temel Y; Visser-Vandewalle V; Carpenter RH
Exp Neurol; 2009 Apr; 216(2):481-9. PubMed ID: 19320006
[TBL] [Abstract][Full Text] [Related]
36. Gait analysis in patients with Parkinson's disease off dopaminergic therapy.
Svehlík M; Zwick EB; Steinwender G; Linhart WE; Schwingenschuh P; Katschnig P; Ott E; Enzinger C
Arch Phys Med Rehabil; 2009 Nov; 90(11):1880-6. PubMed ID: 19887212
[TBL] [Abstract][Full Text] [Related]
37. Recognition of category-related visual stimuli in Parkinson's disease: before and after pharmacological treatment.
Righi S; Viggiano MP; Paganini M; Ramat S; Marini P
Neuropsychologia; 2007 Oct; 45(13):2931-41. PubMed ID: 17662314
[TBL] [Abstract][Full Text] [Related]
38. Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease.
Almeida QJ; Frank JS; Roy EA; Patla AE; Jog MS
Mov Disord; 2007 Sep; 22(12):1735-42. PubMed ID: 17557356
[TBL] [Abstract][Full Text] [Related]
39. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
Hornykiewicz O
Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
[TBL] [Abstract][Full Text] [Related]
40. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
